|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Preparation and characterization of new room temperature ionic liquids 显示文摘 | Braneo L C Rosa J N Moura Ramos J J | 2002 | Chem Eur J2002，，： | 1 |
| 2 | Preparation and characterization of new room temperature ionic liquids显示文摘 | Branco L C Rosa J N Moura Ramos J J et a1 | 2002 | Chem Eur J2002，8，16： | 1 |
| 3 | 显示文摘 | Branco L C Rosa J N Moura Ramos J J | 2002 | Chem Eur J2002，8，： | 1 |
| 4 | Computational analysis of ligand recognition sites of homo-and heteropentameric5-HT3 receptors显示文摘 | Moura Barbosa A J De Rienzo F Ramos M J | 2010 | Eur J Med Chem2010，45，11： | 1 |
| 5 | Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis显示文摘 | Moura L M Ramos S F Zamorano J I | 2007 | J Am Coll Cardiol2007，49，5： | 1 |
| 6 | Preparation and characterization of new room temperature ionic liquids显示文摘 | Branco L C Rosa J N Moura Ramos J J | 2002 | Chem Eur2002，8，16： | 1 |
| 7 | Estimation of the surface tension of a solid: Application to a liquid crystalline polymer显示文摘 | CORREIA N T MOURA RAMOS J J SARAMAGO B J V | 1997 | J Colloid Interface Sci1997，189，： | 1 |
| 8 | Preparation and characterization of new room temperature ionic liquids显示文摘 | Branco L C Rosa J N Moura Ramos J J | 2002 | Chem Eur J2002，8，： | 1 |
| 9 | Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis 显示文摘 | MOURA L M RAMOS SF ZAMORANO J L | 2007 | J Am Coll Cardiol2007，49，5： | 1 |
| 10 | Liquid-liquid extraction and adsorption on solid surfaces appkied to used lubricany oils recovery显示文摘 | Assunç ã o Filho J L Moura L G M Ramos A C S | 2010 | Braz J Cheml Eng2010，27，4： | 1 |
| 11 | Computational analysis of ligand recognition sites of homo-and heteropentameric 5- HT3 receptors显示文摘 | Moura Barbosa A J De Rienzo F Ramos M J | 2010 | Eur J Med Chem2010，45，11： | 1 |
| 12 | Liquid- liquid extraction and adsorption on solid surfaces applied to used lubricant oils recovery显示文摘 | FILHO J L A MOURA L G M RAMOS A C S | 2010 | Brazilian Journal of Chemical Engineering2010，27，4： | 1 |
| 13 | Preparation and characterization of new room tempera- ture ionic liquids显示文摘 | Luls C Branco Joafo N Rosa Joaquim J Moura Ramos | 2002 | Chem Eur J2002，16，： | 1 |
| 14 | Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil显示文摘BACKGROUND Crohn’s disease(CD)and ulcerative colitis(UC)are inflammatory bowel diseases(IBDs)with a remission-relapsing presentation and symptomatic exacerbations that have detrimental impacts on patient quality of life and are associated with a high cost burden,especially in patients with moderate-to-severe disease.The Real-world Data of Moderate-to-Severe Inflammatory Bowel Disease in Brazil(RISE BR)study was a noninterventional study designed to evaluate disease control,treatment patterns,disease burden and health-related quality of life in patients with moderate-to-severe active IBD.We report findings from the prospective follow-up phase of the RISE BR study in patients with active UC or CD.AIM To describe the 12-mo disease evolution and treatment patterns among patients with active moderate-to-severe IBD in Brazil.METHODS This was a prospective,noninterventional study of adult patients with active Crohn’s disease(CD:Harvey-Bradshaw Index≥8,CD Activity Index≥220),inadequate CD control(i.e.,calprotectin>200μg/g or colonoscopy previous results),or active ulcerative colitis(UC:Partial Mayo score≥5).Enrollment occurred in 14 centers from October 2016 to February 2017.The proportion of active IBD patients after 9-12 mo of follow-up,Kaplan-Meier estimates of the time to mild or no activity and a summary of treatment initiation,discontinuation and dose changes were examined.RESULTS The study included 118 CD and 36 UC patients,with mean±SD ages of 43.3±12.6 and 44.9±16.5 years,respectively.The most frequent drug classes at index were biologics for CD(62.7%)and 5-aminosalicylate derivates for UC patients(91.7%).During follow-up,65.3%of CD and 86.1%of UC patients initiated a new treatment at least once.Discontinuations/dose changes occurred in 68.1%of CD patients[median 2.0(IQR:2-5)]and 94.3%of UC patients[median 4.0(IQR:3-7)].On average,CD and UC patients had 4.4±2.6 and 5.0±3.3 outpatient visits,respectively.The median time to first mild or no activity was 319(IQR:239-358)d for CD and 320(IQR:288-358)d for UC patients.At 9-12 mo,22.0%of CD and 20.0%of UC patients had active disease.CONCLUSION Although a marked proportion of active IBD patients achieved disease control within one year,the considerable time to achieve this outcome represents an unmet medical need of the current standard of care in a Brazilian real-world setting. | Ligia Yukie Sassaki Sender J Miszputen Roberto Luiz Kaiser Junior Wilson R Catapani Mauro Bafutto António S Scotton Cyrla Zaltman Julio Pinheiro Baima Hagata S Ramos Mikaell Alexandre Gouvea Faria Carolina D Gonçalves Isabella Miranda Guimaraes Cristina Flores Heda M B S Amarante Rodrigo Bremer Nones JoséMiguel Luz Parente Murilo Moura Lima Júlio Maria Chebli Maria de Lourdes Abreu Ferrari Julia F Campos Maria G P Sanna Odery Ramos Rogério Serafim Parra Jose J R da Rocha Omar Feres Marley R Feitosa Rosana Fusaro Caratin Juliana Tosta Senra Genoile Oliveira Santana | 2021 | World Journal of Gastroenterology2021，27，23： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员